Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8810863 | 0.95 | CYP2C19 (0.46) | CYP2C19TSHRLMNAGRM2GRM3 | |
| SCHEMBL515587 | 0.93 | CYP2C19 (0.44) | CYP2C19TSHRLMNAGRM2GRM3 | |
| SCHEMBL8004566 | 0.92 | CYP2C19 (0.52) | CYP2C19TSHRLMNAGRM2GRM3 | |
| Hydrochloric Acid SCHEMBL11636408 | 0.91 | CYP2C19 (0.42) | CYP2C19TSHRLMNAGRM2GRM3 | |
| SCHEMBL848416 | 0.90 | CYP2C19 (0.50) | CYP2C19TSHRLMNAGRM2GRM3 | |
| SCHEMBL31332713 | 0.86 | CYP2C19 (0.54) | CYP2C19TSHRLMNAGRM2GRM3 | |
| SCHEMBL23603993 | 0.81 | CYP2C19 (0.42) | CYP2C19TSHRLMNAGRM2GRM3 | |
| SCHEMBL3021254 | 0.81 | CYP2C19 (0.54) | CYP2C19TSHRLMNAGRM2GRM3 | |
| SCHEMBL6620534 | 0.79 | TSHR (0.60) | CYP2C19TSHRLMNAGRM2GRM3 | |
| SCHEMBL4072778 | 0.79 | CYP2C19 (0.52) | CYP2C19TSHRLMNAGRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785715-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2014-10-08 | — | — | EP | claimed |
| WO-2013080222-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2013-06-06 | — | — | WO | claimed |
| EP-4561575-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-119101069-A | Spiro compounds and uses thereof | 轩竹生物科技股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2020150417-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-2861566-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | F. Hoffmann-La Roche AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013186159-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-19 | — | — | WO | disclosed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CYP2C19 3201/4885TSHR 4388/4885LMNA 341/4885 |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | CYP2C19 410/4885TSHR 2950/4885LMNA 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.